MIRM
HEALTHCAREMirum Pharmaceuticals Inc
AI Insight
What's Moving MIRM Today?
No stock-specific AI insight has been generated for MIRM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$47.89$125.39
$117.07
Fundamentals
Market Cap$7.5B
P/E Ratio—
EPS$-13.60
Dividend Yield—
Dividend / Share—
ROE-335.8%
Profit Margin-140.2%
Debt / Equity—
Trading
Volume1.2M
Avg Volume (10D)—
Shares Outstanding61.0M
MIRM News
24 articles- Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?Yahoo Finance·Jun 29, 2026
- Enterprise value to EBITDA forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRMTradingView·Jun 29, 2026
- Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data?Yahoo Finance·Jun 25, 2026
- Mirum Shareholders Approve Directors, Auditors and CompensationThe Globe and Mail·Jun 19, 2026
- MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)Yahoo Finance·Jun 17, 2026
- MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA ReviewYahoo Finance·Jun 15, 2026
- Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans ProgressivaYahoo Finance·Jun 14, 2026
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Jun 11, 2026
- Mirum Pharmaceuticals, Inc. Balance Sheet – XETR:08DTradingView·Jun 7, 2026
- Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report?Yahoo Finance·Jun 5, 2026
- Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026Yahoo Finance·Jun 4, 2026
- Mirum Pharmaceuticals (MIRM) Reports Positive Phase 2b Data for Volixibat in PSC at EASL CongressYahoo Finance·Jun 4, 2026
- Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026Yahoo Finance·May 30, 2026
- JPMorgan says large-cap biotech is back as profits and pipelines fuel upsideYahoo Finance·May 28, 2026
- Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline AdvanceMarketbeat·May 27, 2026
- Mirum’s US$600 Million Zero-Coupon Convertible Note Issue Might Change The Case For Investing In Mirum Pharmaceuticals (MIRM)Yahoo Finance·May 25, 2026
- Mirum Pharma: A Rare Disease Growth Story to WatchMarketbeat·May 20, 2026
- Assessing Mirum Pharmaceuticals (MIRM) Valuation After A Strong Year And Recent Share Price PullbackSimply Wall Street·May 16, 2026
- Mirum Pharmaceuticals (MIRM) Is Up 16.9% After Volixibat Phase 2b PSC Itch Data And Big Q1 Loss - Has The Bull Case Changed?Yahoo Finance·May 7, 2026
- Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View RaisedYahoo Finance·May 7, 2026
- Penn Capital Unloads 1.13 Million RealReal Shares Following Massive Stock Run-UpMotley Fool·May 7, 2026
- Mirum Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Mirum Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q1 EarningsYahoo Finance·May 6, 2026
All 24 articles loaded
Price Data
Open$122.90
Previous Close$123.00
Day High$124.57
Day Low$116.29
52 Week High$125.39
52 Week Low$47.89
52-Week Range
$47.89$125.39
$117.07
Fundamentals
Market Cap$7.5B
P/E Ratio—
EPS$-13.60
Dividend Yield—
Dividend / Share—
ROE-335.8%
Profit Margin-140.2%
Debt / Equity—
Trading
Volume1.2M
Avg Volume (10D)—
Shares Outstanding61.0M
About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—